Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition

Executive Summary

The Swiss major has made a larger-than-expected bolt-on buy, using a large chunk of its $13bn windfall from GSK to get hold of a potential cure for spinal muscular atrophy and an additional gene therapy platform, as well as manufacturing capabilities.

Advertisement

Related Content

The US Zolgensma Review: Full Speed Ahead Despite Dose, Stability, Method Uncertainties
Keeping Track: Novartis Scores Big Ahead Of US Memorial Day With Approvals For Gene Therapy Zolgensma, Oncologic Piqray
Roche Confident Spark Therapeutics Acquisition Will Complete In First Half
Novartis Prioritizes Gene Therapy Production With AZ Facility Buy
Rare Disease Roundtable: How Rare Is Too Rare?
Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown
Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fruits
Novartis’s Luxturna Deal Expands Gene Therapy Ambitions
New Dawn At Novartis As Narasimhan Demands Breakthroughs
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100715

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel